Search

Your search keyword '"Mulet-Margalef, Nuria"' showing total 16 results
Start Over Author "Mulet-Margalef, Nuria" Publication Year Range Last 50 years
16 results on '"Mulet-Margalef, Nuria"'

1. Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment

Author

Cabrero-de las Heras, Sara, Hernández-Yagüe, Xavier, González, Andrea, Losa, Ferran, Soler, Gemma, Bugés, Cristina, Baraibar, Iosune, Esteve, Anna, Pardo-Cea, Miguel Ángel, Ree, Anne Hansen, Martínez-Bosch, Neus, Nieva, Maria, Musulén, Eva, Meltzer, Sebastian, Lobato, Tania, Vendrell-Ayats, Carla, Queralt, Cristina, Navarro, Pilar, Montagut, Clara, Grau-Leal, Ferran, Camacho, David, Legido, Raquel, Mulet-Margalef, Núria, and Martínez-Balibrea, Eva

Published
2024
Full Text
View/download PDF

4. Outcomes of patients (pts) treated with novel immunotherapy (IT) agents in phase 1 clinical trials (Ph1-CT) at early lines for advanced disease.

Author

Soto, Juan José, primary, Erasun Lecuona, Carlos, additional, Llop Serna, Sandra, additional, Mulet Margalef, Nuria, additional, Stradella, Agostina, additional, Villanueva, Rafael, additional, Calvo Campos, Mariona, additional, Jove Casulleras, Maria, additional, Cuadra Amor, Carmen, additional, Salazar Soler, Ramon, additional, Gil-Martin, Marta, additional, Martin-Liberal, Juan, additional, and Oliva, Marc, additional

Published
2022
Full Text
View/download PDF

5. Analysis of phase I clinical trials (Ph1-CT) new enrollment patterns in the immuno-oncology era.

Author

Erasun Lecuona, Carlos, primary, Soto, Juan José, additional, Llop Serna, Sandra, additional, Mulet Margalef, Nuria, additional, Stradella, Agostina, additional, Villanueva, Rafael, additional, Calvo Campos, Mariona, additional, Jove Casulleras, Maria, additional, Cuadra Amor, Carmen, additional, Salazar Soler, Ramon, additional, Gil-Martin, Marta, additional, Oliva, Marc, additional, and Martin-Liberal, Juan, additional

Published
2022
Full Text
View/download PDF

7. Tumor-Associated Microbiome: Where Do We Stand?

Author

Oliva, Marc, primary, Mulet-Margalef, Nuria, additional, Ochoa-De-Olza, Maria, additional, Napoli, Stefania, additional, Mas, Joan, additional, Laquente, Berta, additional, Alemany, Laia, additional, Duell, Eric, additional, Nuciforo, Paolo, additional, and Moreno, Victor, additional

Published
2021
Full Text
View/download PDF

8. Clinical practice guidelines for the diagnosis and treatment of patients with soft tissue sarcoma by the Spanish group for research in sarcomas (GEIS)

Author

Garcia del Muro, Xavier, de Alava, Enrique, Artigas, Vicenç, Bague, Silvia, Braña, Alejandro, Cubedo, Ricardo, Cruz, Josefina, Mulet-Margalef, Nuria, Narvaez, Jose A, Martinez Tirado, Oscar, Valverde, Claudia, Verges, Ramona, Viñals, Joan, Martin-Broto, Javier, Spanish Group for Research on Sarcoma, [Garcia del Muro, Xavier] Inst Catala Oncol Hosp, Barcelona, Spain, [Mulet-Margalef, Nuria] Inst Catala Oncol Hosp, Barcelona, Spain, [de Alava, Enrique] Hosp Univ Virgen del Rocio, Seville, Spain, [Martin-Broto, Javier] Hosp Univ Virgen del Rocio, Seville, Spain, [Artigas, Vicenc] Hosp Santa Creu & Sant Pau, Barcelona, Spain, [Bague, Silvia] Hosp Santa Creu & Sant Pau, Barcelona, Spain, [Brana, Alejandro] Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain, [Cubedo, Ricardo] Hosp Puerta Hierro Majadahonda, Madrid, Spain, [Cruz, Josefina] Hosp Univ Canarias, Santa Cruz De Tenerife, Spain, [Narvaez, Jose A.] Hosp Univ Bellvitge, Barcelona, Spain, [Vinals, Joan] Hosp Univ Bellvitge, Barcelona, Spain, [Martinez Tirado, Oscar] Inst Invest Biomed Bellvitge IDIBELL, Barcelona, Spain, [Valverde, Claudia] Hosp Univ Vall Hebron, Barcelona, Spain, and [Verges, Ramona] Hosp Univ Vall Hebron, Barcelona, Spain

Subjects
Cancer Research, medicine.medical_specialty, Soft Tissue Neoplasm, Core-needle-biopsy, medicine.medical_treatment, Antineoplastic Agents, Soft Tissue Neoplasms, Disease, Isolated limb perfusion, 030230 surgery, Toxicology, Targeted therapy, 03 medical and health sciences, Inflammatory myofibroblastic tumor, 0302 clinical medicine, Biopsy, Multidisciplinary management, medicine, Humans, Pharmacology (medical), Doxorubicin plus ifosfamide, Pharmacology, Randomized phase-ii, Soft tissue sarcoma, medicine.diagnostic_test, business.industry, General surgery, Soft tissue, Prognostic-factors, Sarcoma, Evidence-based medicine, medicine.disease, Clear-cell sarcoma, Surgery, Solitary fibrous tumor, Adjuvant chemotherapy, Treatment, Oncology, Chemotherapy, Adjuvant, Spain, 030220 oncology & carcinogenesis, Original Article, business, Clinical practice guidelines, High-dose doxorubicin
Abstract

The authors would like to thank Ron Clapp, and GEIS Clinical Research Center for their assistance in the preparation of the manuscript, Garcia Del Muro, X., De Alava, E., Artigas, V., Bague, S., Braña, A., Cubedo, R., Cruz, J., Mulet-Margalef, N., Narvaez, J.A., Martinez Tirado, O., Valverde, C., Verges, R., Viñals, J., Martin-Broto, J.

Published
2015

11. Active surveillance before sequential targeted therapy in patients with metastatic renal cell carcinoma.

Author

Jove, Maria, primary, Etxaniz, Olatz, additional, Sala, Nuria, additional, Font, Albert, additional, Jimenez Colomo, Laura, additional, Saigi, Maria, additional, Recalde, Sabela, additional, Navarro-Perez, Valentín, additional, Barretina-Ginesta, Pilar, additional, Ochoa de Olza, Maria, additional, Mulet-Margalef, Nuria, additional, and Garcia del Muro, Xavier, additional

Published
2015
Full Text
View/download PDF

12. Phase II study of gemcitabine (GEM) plus sirolimus (SIR) in previously treated patients with advanced soft tissue sarcoma (STS): A Spanish Group for Research on Sarcomas (GEIS) study.

Author

Garcia del Muro, Xavier, primary, Lopez-Pousa, Antonio, additional, Martinez-Trufero, Javier, additional, Martin Broto, Javier, additional, Cubedo, Ricardo, additional, Lavernia, Javier, additional, Redondo, Andrés, additional, Lopez-Martin, Jose A., additional, Mulet-Margalef, Nuria, additional, Sanjuan, Xavier, additional, and M. Tirado, Oscar, additional

Published
2014
Full Text
View/download PDF

14. Presentation and treatment of HER2-positive metastatic breast cancer patients already treated with adjuvant trastuzumab.

Author

Torrejon, Davis Yuri, primary, Di Cosimo, Serena, additional, Sanchez-Olle, Gessami, additional, Balmaña, Judith, additional, Bellet, Meritxell, additional, Gomez, Patricia, additional, Saura, Cristina, additional, Perez-Garcia, Jose Manuel, additional, Muñoz-Couselo, Eva, additional, Vidal, Maria, additional, Ortega, Vanesa, additional, De Mattos-Arruda, Leticia, additional, Oliveira, Mafalda, additional, Mulet-Margalef, Nuria, additional, Tabernero, Josep, additional, and Cortes, Javier, additional

Published
2012
Full Text
View/download PDF

15. RASand RAFmutation status in the selection of patients for anti-EGFR therapy

Author

Mulet-Margalef, Nuria, Domènech, Marta, and Salazar, Ramon

Abstract

Anti-EGFR therapy in combination or not with chemotherapy is one of the mainstays of treatment for advanced colorectal cancer. KRASexon 2 mutations have been validated as negative predictors of response, despite of it, an important percentage of patients do not benefit from anti-EGFR therapy. Factors like other RASand BRAFmutations could contribute to primary resistance to cetuximab and panitumumab. Evidence surrounding RASand BRAFstatus determination before anti-EGFR therapy administration is reviewed here.

Published
2016
Full Text
View/download PDF

16. [Neuroendocrine tumors: the age of targeted therapies].

Author

Capdevila J, Argilés G, Mulet-Margalef N, and Tabernero J

Subjects
Everolimus, Humans, Immunosuppressive Agents therapeutic use, Sirolimus analogs & derivatives, Sirolimus therapeutic use, Gastrointestinal Neoplasms drug therapy, Molecular Targeted Therapy, Neuroendocrine Tumors drug therapy, Pancreatic Neoplasms drug therapy
Abstract

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are the second most prevalent group of advanced gastrointestinal tract tumors. Resources invested in research on this patient population have exponentially increased in recent years, and this has become one of the most attractive fields for oncological research. Several proangiogenic proteins have been found to be overexpressed in GEP-NETs, including vascular endothelial growth factor and its receptors and the more closely related intracellular signaling pathways such as the epidermal growth factor pathway, type I insulin-like growth factor receptor, and the PI3K-(PTEN)-AKT-mTOR pathway. The recent results of the three most important Phase III studies in GEP-NETs have allowed for approval of two targeted agents, sunitinib and everolimus, for the treatment of patients with pancreatic neuroendocrine tumors after decades of minimal advances in this population., (Copyright © 2011 SEEN. Published by Elsevier Espana. All rights reserved.)

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results